.. Activité-antileucémique-de-l-'arsthinol, , p.90

.. Propriétés-des-nanosuspensions-d-'arsthinol, , p.91

. Pharmacocinétique and .. Et-de-ses-nanosuspensions, , p.93

.. Pharmacocinétique-plasmatique, , p.93

.. En-solution and .. , , p.95

.. Etude-du-métabolisme-de-l-'arsthinol, , p.97

.. Mécanisme-de-transformation, , p.97

C. , , p.99

F. Liste-des, , p.102

T. Liste-des, , p.105

S. Waxman and K. C. Anderson, History of the Development of Arsenic Derivatives in Cancer Therapy, The Oncologist, vol.6, issue.90002, pp.3-10, 2001.
DOI : 10.1634/theoncologist.6-suppl_2-3

]. C. Forkner and T. Scott, ARSENIC AS A THERAPEUTIC AGENT IN CHRONIC MYELOGENOUS LEUKEMIA, Journal of the American Medical Association, vol.97, issue.1, pp.3-5, 1931.
DOI : 10.1001/jama.1931.02730010007002

K. Q. Sun, Y. Yang, L. Chen, Z. W. Zhou, Y. T. Fang et al.,

Z. Chen, Z. Y. Chen, S. Wang, R. Gibaud, P. Alfonsi et al., Blood J. Organomet. Chem. J. Organomet. Chem. Am. J. Trop. Med, vol.89, issue.692, pp.3354-3360, 1997.

L. Hyg, R. H. Goldman, M. Preston, and . Meister, Dermatologica, vol.3, issue.113, pp.262-265, 1954.

]. B. Cristau, M. E. Chabas, and M. Placidi, Ann. Pharm. Fr, vol.33, issue.8, pp.577-589, 1975.

A. Gregus and . Gyurasics, Role of glutathione in the biliary excretion of the arsenical drugs trimelarsan and melarsoprol, Biochemical Pharmacology, vol.59, issue.11, pp.1375-1385, 2000.
DOI : 10.1016/S0006-2952(00)00263-X

B. Cristau, M. Placidi, and P. Audibert, J. Pharmacol, vol.4, pp.199-207, 1973.

S. C. Elliot and B. R. Loper, Improved absorption tube for arsenic determinations, Analytical Chemistry, vol.46, issue.14, pp.2256-2257, 1974.
DOI : 10.1021/ac60350a038

V. Devesa, L. Del-razo, B. Adair, Z. Drobná, S. Waters et al.,

. Thomas, J. Anal. At. Spectrom, vol.19, pp.1460-1467, 2004.

M. F. Hughes, E. M. Kenyon, B. C. Edwards, C. T. Mitchell, L. M. Razo et al., Toxicol. Appl. Pharmacol, pp.191-202, 2003.

R. Harrison and F. Radic, Biol. Med, vol.33, pp.774-797, 2002.

E. Pick and Y. Keisari, A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture, Journal of Immunological Methods, vol.38, issue.1-2, pp.161-170, 1980.
DOI : 10.1016/0022-1759(80)90340-3

B. Cristau, M. Placidi, and P. Audibert, Med. Trop. (Mars), vol.32, pp.275-283, 1972.

I. Ajana, A. Astier, and S. Gibaud, Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells, Journal of Pharmacy and Pharmacology, vol.55, issue.10, pp.1295-1301, 2009.
DOI : 10.1093/toxsci/55.2.460

I. Ajana, A. Astier, and S. Gibaud, Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells, Journal of Pharmacy and Pharmacology, vol.55, issue.10, pp.1295-1301, 2009.
DOI : 10.1093/toxsci/55.2.460

R. N. Alyautdin, E. B. Tezikov, P. Ramge, D. A. Kharkevich, D. J. Begley et al., brain perfusion study, Journal of Microencapsulation, vol.46, issue.1, pp.67-74, 1998.
DOI : 10.1111/j.1471-4159.1986.tb01760.x

. Anonyme, New and nonofficial remedies; arsthinol, JAMA, vol.152, p.531, 1953.

. Anonyme, Action of atoxyl on Eyes, Cal State J Med, vol.8, p.384, 1910.

H. V. Aposhian, R. A. Zakharyan, M. D. Avram, M. J. Kopplin, and M. L. Wollenberg, Oxidation and detoxification of trivalent arsenic species, Toxicology and Applied Pharmacology, vol.193, issue.1, pp.1-8, 2003.
DOI : 10.1016/S0041-008X(03)00324-7

H. V. Aposhian, R. A. Zakharyan, M. D. Avram, A. Sampayo-reyes, and M. L. Wollenberg, A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species, Toxicol Appl Pharmacol, vol.198, pp.327-335, 2004.

S. M. Aronson, Arsenic and old myths. Rhode Island medicine, pp.233-234, 1994.

J. T. Barbey and S. Soignet, Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Annals of internal medicine, pp.842-843, 2001.

A. Béchamp, De l'action de la chaleur sur l'arséniate d'aniline et de la formation d'un anilide de l'acide arsénique, pp.1172-1175

D. Begley, The Blood-brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System, Journal of Pharmacy and Pharmacology, vol.53, issue.Suppl. 286, pp.136-146, 1996.
DOI : 10.1111/j.1471-4159.1989.tb08522.x

P. F. Belcastro, Arsenic trioxide: New uses for an old remedy, J Am Pharm Assoc, pp.41-366, 2001.

B. J. Berger and A. H. Fairlamb, Properties of melarsamine hydrochloride (Cymelarsan) in aqueous solution., Antimicrobial Agents and Chemotherapy, vol.38, issue.6, pp.1298-1302, 1994.
DOI : 10.1128/AAC.38.6.1298

C. Bhuvaneswaran, The influence of phosphorylation state ratio on energy conservation in mitochondria treated with inorganic arsenate, Biochemical and Biophysical Research Communications, vol.90, issue.4, pp.1201-1206, 1979.
DOI : 10.1016/0006-291X(79)91164-1

T. Blunk, D. F. Hochstrasser, J. C. Sanchez, B. W. Müller, and R. H. Müller, Colloidal carriers for intravenous drug targeting: Plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis, Electrophoresis, vol.984, issue.1, pp.1382-1387, 1993.
DOI : 10.1021/bk-1987-0343.ch016

K. Bolia-wilson, Bleecker and ML, Neuropsychological impairment following inorganic arsenic exposure, J occup Med, vol.29, pp.500-503, 1987.

U. Bronner, R. Brun, F. Doua, O. Ericsson, C. Burri et al., Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized, Tropical Medicine and International Health, vol.79, issue.11, pp.913-917, 1998.
DOI : 10.1016/0035-9203(85)90195-6

C. Burri, T. Baltz, C. Giroud, F. Doua, H. A. Welker et al., Pharmacokinetic Properties of the Trypanocidal Drug Melarsoprol, Chemotherapy, vol.39, issue.4, pp.225-234, 1993.
DOI : 10.1159/000239130

G. Q. Chen, J. Zhu, X. G. Shi, J. H. Ni, H. J. Zhong et al., In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As 2 O 3 ) in the treatment of acute promyelocytic leukemia: As 2 O 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR?/PML proteins, Blood, vol.88, pp.1052-1061, 1996.

P. Couvreur, B. Kante, M. Roland, P. Guiot, P. Bauduin et al., Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties, Journal of Pharmacy and Pharmacology, vol.63, issue.1, pp.331-332, 1979.
DOI : 10.1002/app.1966.070100208

B. Cristau, E. Chabas, and M. Placidi, Voies et cinétiques d'excrétion de l'arsenic chez le cobaye après injection de divers médicaments organo-arséniés, Ann Pharm Fr, vol.33, pp.577-589, 1975.

B. Cristau, M. Placidi, and P. Audibert, Elimination biliaire chez le rat de quelques médicaments organoarseniés, Journal de Pharmacologie, vol.4, pp.199-207, 1973.

E. G. Cutler and E. H. Bradford, Action of Iron, Cod-liver Oil, and Arsenic on the Globular Richness of the Blood, The American Journal of the Medical Sciences, vol.75, issue.149, pp.74-84, 1878.
DOI : 10.1097/00000441-187801000-00004

J. Cuzick, S. Evans, M. Gillman, P. Evans, and D. A. , Medicinal arsenic and internal malignancies, British Journal of Cancer, vol.45, issue.6, pp.904-911, 1982.
DOI : 10.1038/bjc.1982.143

L. Edebo and N. Richardson, Enhancement of hydrophobic interaction, negative charge and phagocytosis by dinitrophenyl ligand coupling to salmonella typhimurium 395 ms. International archives of allergy and applied immunology, pp.345-352, 1985.

P. Ehrlich and A. Bertheim, Derivatives of oxyarylarsinic acids and process of making same, p.148, 1911.

O. Ericsson, E. K. Schweda, U. Bronner, L. Rombo, M. Friden et al., Determination of melarsoprol in biological fluids by high-performance liquid chromatography and characterisation of two stereoisomers by nuclear magnetic resonance spectroscopy, Journal of Chromatography B: Biomedical Sciences and Applications, vol.690, issue.1-2, pp.243-251, 1997.
DOI : 10.1016/S0378-4347(96)00418-5

H. W. Florey, The transport of materials across the capillary wall Quarterly journal of experimental physiology and cognate medical sciences, pp.117-128, 1964.

C. E. Forkner and T. F. Scott, ARSENIC AS A THERAPEUTIC AGENT IN CHRONIC MYELOGENOUS LEUKEMIA, Journal of the American Medical Association, vol.97, issue.1
DOI : 10.1001/jama.1931.02730010007002

, JAMA, vol.97, pp.3-5, 1931.

E. A. Friedheim, Melarsen oxide in the treatment of human african trypanosomiasis. Ann Trop Med, pp.357-363, 1948.

E. A. Friedheim, A Five Day Peroral Treatment of Yaws with STB, a New Trivalent Arsenical 1, The American Journal of Tropical Medicine and Hygiene, vol.1, issue.2
DOI : 10.4269/ajtmh.1949.s1-29.185

, Am J Trop Med Hyg, pp.185-188, 1949.

E. A. Friedheim, Mel B in the treatment of human trypasonomiasis, Am J Trop Med Hyg, vol.29, pp.173-180, 1949.

E. A. Friedheim, Heterocyclic metal and sulfur organic compounds, p.664432, 1953.

S. Fujisawa, R. Ohno, K. Shigeno, N. Sahara, S. Nakamura et al., Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide, Cancer Chemotherapy and Pharmacology, vol.198, issue.4, pp.485-493, 2007.
DOI : 10.1007/s00280-006-0288-4

L. Gao, D. Zhang, M. Chen, C. Duan, W. Dai et al., Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions, International Journal of Pharmaceutics, vol.355, issue.1-2, pp.321-327, 2008.
DOI : 10.1016/j.ijpharm.2007.12.016

A. Gessner, R. Waicz, A. Lieske, B. R. Paulke, K. Mäder et al., Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption, International Journal of Pharmaceutics, vol.196, issue.2, pp.245-249, 2000.
DOI : 10.1016/S0378-5173(99)00432-9

R. K. Gherardi, P. Chariot, M. Vanderstigel, D. Malapert, J. Verroust et al., Organic arsenic-induced guillain-barre-like syndrome due to melarsoprol: A clinical, electrophysiological, and pathological study. Muscle Nerve, pp.637-645, 1990.

M. Gianni, M. H. Koken, M. K. Chelbi-alix, G. Benoit, M. Lanotte et al., Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells, Blood, vol.91, pp.4300-4310, 1998.

S. Gibaud, R. Alfonsi, P. Mutzenhardt, I. Fries, and A. Astier, (2-Phenyl-[1,3,2]dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity, Journal of Organometallic Chemistry, vol.691, issue.5, pp.1081-1084, 2006.
DOI : 10.1016/j.jorganchem.2005.11.007

URL : https://hal.archives-ouvertes.fr/hal-00125073

S. Gibaud, J. P. Andreux, C. Weingarten, M. Renard, and P. Couvreur, Increased bone marrow toxicity of doxorubicin bound to nanoparticles, European Journal of Cancer, vol.30, issue.6, pp.820-826, 1994.
DOI : 10.1016/0959-8049(94)90299-2

URL : https://hal.archives-ouvertes.fr/hal-01383605

S. Gibaud, M. Demoy, J. P. Andreux, C. Weingarten, B. Gouritin et al., Cells Involved in the Capture of Nanoparticles in Hematopoietic Organs, Journal of Pharmaceutical Sciences, vol.85, issue.9, pp.944-950, 1996.
DOI : 10.1021/js960032d

URL : https://hal.archives-ouvertes.fr/hal-00399624

L. Goldman, R. H. Preston, and M. Meister, Arsthinol (Balarsen) in Dermatology, Dermatology, vol.113, issue.6, pp.369-374, 1956.
DOI : 10.1159/000256212

J. J. Gordon and J. H. Quastel, Effects of Organic Arsenic Compounds on Tissue Enzymes and Proteins and on Tissue Metabolism, Nature, vol.159, issue.4029, pp.97-98, 1947.
DOI : 10.1038/159097b0

J. J. Gordon and J. H. Quastel, Effects of organic arsenicals on enzyme systems, Biochemical Journal, vol.42, issue.3, pp.337-350, 1948.
DOI : 10.1042/bj0420337

Z. Gregus and A. Gyurasics, Role of glutathione in the biliary excretion of the arsenical drugs trimelarsan and melarsoprol, Biochemical Pharmacology, vol.59, issue.11, pp.1375-1385, 2000.
DOI : 10.1016/S0006-2952(00)00263-X

N. H. Greig, Drug delivery to the brain by blood-brain barrier circumvention and drug modification Implications of the blood-brain barrier and its manipulation, pp.311-367, 1989.

A. E. Gulyaev, S. E. Gelperina, I. N. Skidan, A. S. Antropov, G. Y. Kivman et al.,

, Pharm Res, vol.16, pp.1564-1569, 1999.

L. Haller, H. Adams, F. Merouze, and A. Dago, Clinical and Pathological Aspects of Human African Trypanosomiasis (T. B. Gambiense) with Particular Reference to Reactive Arsenical Encephalopathy, The American Journal of Tropical Medicine and Hygiene, vol.35, issue.1, pp.94-99, 1986.
DOI : 10.4269/ajtmh.1986.35.94

S. M. Harrison, R. W. Harris, and J. D. Bales, Attempt to correlate urine arsenic excretion with clinical course during melarsoprol therapy of patients with Rhodesian trypanosomiasis. The American journal of tropical medicine and hygiene, pp.632-636, 1997.

R. Hille, The mononuclear molybdenum enzymes. Chemical reviews, pp.2757-2816, 1996.

C. F. Hiskey and F. F. Cantwell, Ultraviolet Spectrum Correlations with the Conjugate Acid-Base Species of Acetarsone and Arsthinol, Journal of Pharmaceutical Sciences, vol.57, issue.12, pp.2105-2111, 1968.
DOI : 10.1002/jps.2600571217

D. M. Hockenbery, Z. N. Oltvai, X. M. Yin, C. L. Milliman, and S. J. Korsmeyer, Bcl-2 functions in an antioxidant pathway to prevent apoptosis, Cell, vol.75, issue.2, pp.241-251, 1993.
DOI : 10.1016/0092-8674(93)80066-N

G. Hudson and J. M. Yoffey, Ultrastructure of reticuloendothelial elements in guinea-pig bone marrow, Journal of Anatomy, vol.103, pp.515-525, 1968.

C. A. Hunter, F. W. Jennings, J. H. Adams, M. Murragh, and P. G. Kennedy, Subcurative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis, The Lancet, vol.339, issue.8799, pp.956-958, 1992.
DOI : 10.1016/0140-6736(92)91531-C

M. M. Hussain, R. W. Mahley, J. K. Boyles, P. A. Lindquist, W. J. Brecht et al., Chylomicron metabolism. Chylomicron uptake by bone marrow in different animal species, J Biol Chem, vol.264, pp.17931-17938, 1989.

L. Illum and S. S. Davis, Targeting of colloidal particles to the bone marrow, Life Sciences, vol.40, issue.16, pp.1553-1560, 1987.
DOI : 10.1016/0024-3205(87)90120-2

L. Illum and S. S. Davis, The targeting of drugs parenterally by use of microspheres, J Parenter Sci Technol, vol.36, pp.242-248, 1982.

L. Illum, S. S. Davis, R. H. Müller, E. Mak, and P. West, The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a blockcopolymer - poloxamine 908, Life Sciences, vol.40, issue.4, pp.367-374, 1987.
DOI : 10.1016/0024-3205(87)90138-X

K. Ishitsuka, S. Suzuki, S. Hanada, A. Utsunomiya, S. Takeuchi et al., Arsenic acid as well as retinoic acids have therapeutic potential to adult T cell leukemia, Blood, issue.1, pp.90-324, 1997.

R. Jackson and J. W. Grainge, Arsenic and cancer, Can Med Assoc J, vol.113, pp.396-401, 1975.

Y. Jing, J. Dai, R. M. Chalmers-redman, W. G. Tatton, and S. Waxman, Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxidedependent pathway, Blood, vol.94, pp.2102-2111, 1999.

J. U. Junghanns and R. H. Müller, Nanocrystal technology, drug delivery and clinical applications

, Int J Nanomedicine, vol.3, pp.295-309, 2008.

E. V. Kandel and G. V. Leroy, CHRONIC ARSENICAL POISONING DURING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA, Archives of Internal Medicine, vol.60, issue.5, pp.846-866, 1937.
DOI : 10.1001/archinte.1937.00180050113008

O. Kayser, A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications, International Journal of Pharmaceutics, vol.214, issue.1-2, pp.83-85, 2001.
DOI : 10.1016/S0378-5173(00)00640-2

J. Keiser and C. Burri, Physico-chemical properties of the trypanocidal drug melarsoprol, Acta Tropica, vol.74, issue.1, pp.101-104, 2000.
DOI : 10.1016/S0001-706X(99)00081-9

J. Keiser, O. Ericsson, and C. Burri, Investigations of the metabolites of the trypanocidal drug melarsoprol. Clinical pharmacology and therapeutics, pp.478-488, 2000.

M. H. Koken, G. Linares-cruz, F. Quignon, A. Viron, M. K. Chelbi-alix et al., The PML growth-suppressor has an altered expression in human oncogenesis, Oncogene, vol.10, pp.1315-1324, 1995.

A. Konig, L. Wrazel, R. P. Warrell, R. Rivi, P. P. Pandolfi et al., Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines, Blood, vol.90, pp.562-570, 1997.

S. Krajewski, M. Krajewska, A. Shabaik, T. Miyashita, H. G. Wang et al., Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2, Am J Pathol, vol.145, pp.1323-1336, 1994.

H. Kreppel, F. X. Reichl, L. Szinicz, B. Fichtl, and W. Forth, Efficacy of various dithiol compounds in acute As2O3 poisoning in mice, Archives of Toxicology, vol.42, issue.suppl, pp.387-392, 1990.
DOI : 10.2131/jts.8.197

J. Kreuter, Application of nanoparticles for the delivery of drugs to the brain, International Congress Series, vol.1277, pp.85-94, 2005.
DOI : 10.1016/j.ics.2005.02.014

J. Kreuter, R. N. Alyaudtin, D. A. Kharkevich, and A. A. Ivanov, Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles), Brain Research, vol.674, issue.1, pp.171-174, 1995.
DOI : 10.1016/0006-8993(95)00023-J

J. Kreuter, V. E. Petrov, D. A. Kharkevich, and R. N. Alyaudtin, Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood???brain barrier using surfactant-coated nanoparticles, Journal of Controlled Release, vol.49, issue.1, pp.81-87, 1997.
DOI : 10.1016/S0168-3659(97)00061-8

J. Kreuter, Drug targeting with nanoparticles, European Journal of Drug Metabolism and Pharmacokinetics, vol.40, issue.3, pp.253-256, 1994.
DOI : 10.1111/j.2042-7158.1989.tb06429.x

J. Kreuter, Nanoparticulate systems for brain delivery of drugs. Advanced drug delivery reviews, pp.65-81, 2001.
DOI : 10.1016/j.addr.2012.09.015

J. Kreuter, D. Shamenkov, V. Petrov, P. Ramge, K. Cychutek et al., Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier, Journal of Drug Targeting, vol.10, issue.4, pp.317-325, 2002.
DOI : 10.1080/10611860290031877

B. H. Kuhn, Balarsen: A new oral arsenical in the treatment of pustular bacterid

W. Med and J. , , pp.48-49, 1956.

C. R. Kumana, W. Y. Au, N. S. Lee, M. Kou, R. W. Mak et al., Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. European journal of clinical pharmacology, pp.521-526, 2002.

Y. L. Kwong and D. Todd, Delicious poison: Arsenic trioxide for the treatment of leukemia, Blood, vol.89, pp.3487-3488, 1997.

H. A. Langenhan, A century of the united states pharmacopoeia. 1820-1920, p.1153, 1918.

P. Li, D. Nijhawan, I. Budihardjo, S. M. Srinivasula, M. Ahmad et al., Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade, Cell, vol.91, issue.4, pp.479-489, 1997.
DOI : 10.1016/S0092-8674(00)80434-1

G. G. Liversidge, K. C. Cundy, J. Bishop, and D. Czekai, , 1991.

D. Livingstone, Arsenic as a remedy for the tse tse bite, Br Med J, vol.1858, issue.1, pp.360-361

E. H. Loughlin, A. A. Joseph, and W. G. Mullin, The treatment of amebiasis with arsthinol Antibiotics and Chemotherapy, pp.647-648, 1954.

M. Luck, W. Schroder, B. R. Paulke, T. Blunk, and R. H. Müller, Complement activation by model drug carriers for intravenous application: determination by two-dimensional electrophoresis, Biomaterials, vol.20, issue.21, pp.2063-2068, 1999.
DOI : 10.1016/S0142-9612(99)00110-6

K. Manjunath and V. Venkateswarlu, Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration, Journal of Controlled Release, vol.107, issue.2, pp.215-228, 2005.
DOI : 10.1016/j.jconrel.2005.06.006

D. N. Mazumder, J. Das-gupta, A. K. Chakraborty, A. Chatterjee, D. Das et al., Environmental pollution and chronic arsenicosis in south calcutta. Bulletin of the World Health Organization, pp.481-485, 1992.

S. M. Moghimi, L. Illum, and S. S. Davis, Physiopathological and physicochemical considerations in targeting of colloids and drug carriers to the bone marrow, Critical Reviews in Therapeutic Drug Carrier Systems, vol.7, pp.187-209, 1990.

S. M. Moghimi, I. S. Muir, L. Illum, S. S. Davis, and V. Kolb-bachofen, Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1179, issue.2, pp.157-165, 1993.
DOI : 10.1016/0167-4889(93)90137-E

S. M. Moghimi and H. M. Patel, Differential properties of organ-specific serum opsonins for liver and spleen macrophages, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.984, issue.3, pp.379-383, 1989.
DOI : 10.1016/0005-2736(89)90306-4

S. M. Moghimi and H. M. Patel, Calcium as a possible modulator of Kupffer cell phagocytic function by regulating liver-specific opsonic activity, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1028, issue.3, pp.304-308, 1990.
DOI : 10.1016/0005-2736(90)90180-V

S. M. Moghimi, C. J. Porter, I. S. Muir, L. Illum, and S. S. Davis, Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating. Biochemical and biophysical research communications, pp.861-866, 1991.

D. H. Moore and H. Ruska, The fine structure of capillaries and small arteries. The Journal of biophysical and biochemical cytology, pp.457-462, 1957.

H. Most, F. V. Assendelft, J. Miller, M. B. Milberg, and E. B. Rossman, Arsthinol (Balarsen), a new trivalent arsenical for the treatment of intestinal amebiasis and other intestinal protozoa

, Am J Trop Med Hyg, vol.3, pp.262-265, 1954.

Z. M. Mu, K. V. Chin, J. H. Liu, G. Lozano, and K. S. Chang, PML, a growth suppressor disrupted in acute promyelocytic leukemia. Molecular and cellular biology, pp.6858-6867, 1994.

B. W. Müller and R. H. Müller, Particle Size Analysis of Latex Suspensions and Microemulsions by Photon Correlation Spectroscopy, Journal of Pharmaceutical Sciences, vol.73, issue.7, pp.915-918, 1984.
DOI : 10.1002/jps.2600730713

R. H. Müller, R. Becker, B. Kruss, and K. Peters, Pharmaceutical nanosuspensions for medicament administration as system of increased saturation solubility and rate of solution, 1998.

R. H. Müller, Colloidal drug carriers for controlled drug delivery and targeting. Modification, characterization and in vivo distribution, 1991.

R. H. Müller, C. Jacobs, and O. Kayser, Nanosuspensions as particulate drug formulations in therapy, Advanced Drug Delivery Reviews, vol.47, issue.1, pp.3-19, 2001.
DOI : 10.1016/S0169-409X(00)00118-6

R. H. Müller and C. M. Keck, Challenges and solutions for the delivery of biotech drugs ??? a review of drug nanocrystal technology and lipid nanoparticles, Journal of Biotechnology, vol.113, issue.1-3, pp.151-170, 2004.
DOI : 10.1016/j.jbiotec.2004.06.007

R. H. Müller, K. Peters, R. Becker, and B. Kruss, Nanosuspensions for the I.V. administration of poorly soluble drugs -stability during sterilization and long-term storage

R. Bioact and . Mater, , pp.574-575, 1995.

R. H. Müller, D. Rühl, M. Lück, and B. R. Paulke, Influence of fluorescent labelling of polystyrene particles on phagocytic uptake, surface hydrophobicity, and plasma protein adsorption. Pharmaceutical research, pp.18-24, 1997.

M. M. Nerurkar, P. S. Burton, and R. T. Borchardt, The use of surfactants to enhance the permeability of peptides through caco-2 cells by inhibition of an apically polarized efflux system, Pharmaceutical Research, vol.13, issue.4, pp.528-534, 1996.
DOI : 10.1023/A:1016033702220

F. H. Nielsen and E. Uthus, Arsenic, in frieden F(ed): Biochemistry of the essential ultratrace elements, p.319, 1981.

C. Niu, H. Yan, T. Yu, H. P. Sun, J. X. Liu et al., Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients, Blood, vol.94, pp.3315-3324, 1999.

L. Nodenot, J. Ridet, A. Chartol, and G. Desmoulins, A new drug against sleeping sickness

W. Mel, Med Trop (Marseille), pp.679-698, 1960.

J. C. Olivier, Drug transport to brain with targeted nanoparticles, NeuroRX, vol.92, issue.1, pp.108-119, 2005.
DOI : 10.1073/pnas.92.12.5592

Z. N. Oltvai, C. L. Milliman, and S. J. Korsmeyer, Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death, Cell, vol.74, issue.4, pp.609-619, 1993.
DOI : 10.1016/0092-8674(93)90509-O

V. B. Patravale, A. A. Date, and R. M. Kulkarni, Nanosuspensions: a promising drug delivery strategy, Journal of Pharmacy and Pharmacology, vol.32, issue.7, pp.827-840, 2004.
DOI : 10.1016/S0169-409X(97)00136-1

URL : http://onlinelibrary.wiley.com/doi/10.1211/0022357023691/pdf

L. Pearce, TRYPARSAMIDE TREATMENT OF AFRICAN SLEEPING SICKNESS, Science, vol.61, issue.1569, pp.90-92, 1925.
DOI : 10.1126/science.61.1569.90-b

J. Pépin and F. Milord, The Treatment of Human African Trypanosomiasis, Adv Parasitol, vol.33, pp.1-47, 1994.
DOI : 10.1016/S0065-308X(08)60410-8

K. Peters, S. Leitzke, J. E. Diederichs, K. Borner, H. Hahn et al., Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium avium infection. The Journal of antimicrobial chemotherapy, pp.77-83, 2000.

B. Pitard, M. Bello-roufa?, O. Lambert, P. Richard, L. Desigaux et al., Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer, Nucleic Acids Research, vol.32, issue.20, p.159, 2004.
DOI : 10.1093/nar/gnh153

URL : https://academic.oup.com/nar/article-pdf/32/20/e159/3888775/gnh153.pdf

C. J. Porter, M. C. Davies, S. S. Davis, and L. Illum, Microparticulate systems for site-specific therapy -bone marrow targeting Polymeric site-specific pharmacotherapy, pp.157-203, 1994.

C. J. Porter, S. M. Moghimi, M. C. Davies, S. S. Davis, and L. Illum, Differences in the molecular weight profile of poloxamer 407 affect its ability to redirect intravenously administered colloids to the bone marrow, International Journal of Pharmaceutics, vol.83, issue.1-3, pp.273-276, 1992.
DOI : 10.1016/0378-5173(82)90033-3

C. J. Porter, S. M. Moghimi, L. Illum, and S. S. Davis, The polyoxyethylene/polyoxypropylene block co-polymer Poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow, FEBS Letters, vol.88, issue.1, pp.62-66, 1992.
DOI : 10.1073/pnas.88.11.4771

URL : http://onlinelibrary.wiley.com/doi/10.1016/0014-5793(92)80655-Z/pdf

B. E. Rabinow, Nanosuspensions in drug delivery, Nature Reviews Drug Discovery, vol.710, issue.Suppl. 2, pp.785-796, 2004.
DOI : 10.1016/0006-8993(95)01375-X

S. I. Rapoport, K. Ohno, W. R. Fredericks, and K. D. Pettigrew, Regional cerebrovascular permeability to [14C]sucrose after osmotic opening of the blood-brain barrier, Brain Research, vol.150, issue.3, pp.653-657, 1978.
DOI : 10.1016/0006-8993(78)90832-6

J. Rive, F. Seric, I. Kone, and E. Bertrand, Considérations sur le traitement de la trypanosomiase humaine africaine à trypanosoma gambiense (méthodes, résultats, encéphalopathie arsenicale, orage liquidien) Médecine d'Afrique Noire, pp.379-387, 1973.

D. H. Robertson, The treatment of sleeping sickness (mainly due to Trypanosoma rhodesiense) with melarsoprol, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol.32, issue.2, pp.122-133, 1963.
DOI : 10.1001/jama.1946.02870400029006

P. Rousselot, J. Larghero, S. Labaume, J. Poupon, M. Chopin et al., Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice, European Journal of Haematology, vol.8, issue.3, pp.166-171, 2004.
DOI : 10.1038/sj.leu.2402599

M. Rowland and T. N. Tozer, Clinical Pharmacokinetics. Lea and Febiger, 1980.

A. C. Schmidt, J. Koppelt, M. Neustadt, and M. Otto, Mass spectrometric evidence for different complexes of peptides and proteins with arsenic(III), arsenic(V), copper(II), and zinc(II) species, Rapid Communications in Mass Spectrometry, vol.11, issue.2, pp.153-163, 2007.
DOI : 10.1002/rcm.2823

N. Schöler, K. Krause, O. Kayser, R. H. Müller, K. Borner et al., Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis, Antimicrobial Agents and Chemotherapy, vol.45, issue.6, pp.1771-1779, 2001.
DOI : 10.1128/AAC.45.6.1771-1779.2001

D. A. Sears, History of the treatment of chronic myelocytic leukemia. The American journal of the medical sciences, pp.85-86, 1988.

Z. X. Shen, G. Q. Chen, J. H. Ni, X. S. Li, S. M. Xiong et al., Use of arsenic trioxide (As 2 O 3 ) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients, pp.3354-3360, 1997.

G. Sina, N. Triolo, P. Trova, and J. M. Clabaut, Arsenic encephalopathy in the treatment of human african trypanosomiasis due to T. gambiense (apropos of 16 cases) Annales de la Societe belge de médecine tropicale, pp.67-74, 1977.

S. L. Soignet, S. R. Frankel, D. Douer, M. S. Tallman, H. Kantarjian et al., United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia, Journal of Clinical Oncology, vol.19, issue.18, pp.3852-3860, 2001.
DOI : 10.1200/JCO.2001.19.18.3852

S. L. Soignet, P. Maslak, Z. G. Wang, S. Jhanwar, E. Calleja et al., Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide, New England Journal of Medicine, vol.339, issue.19, pp.1341-1348, 1998.
DOI : 10.1056/NEJM199811053391901

S. L. Soignet, W. P. Tong, S. Hirschfeld, and R. P. Warrell, Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer chemotherapy and pharmacology, pp.417-421, 1999.

P. Speiser, New drug formulations as the result of recent technological development efforts

, Acta Pharm Suec, vol.10, pp.381-400, 1973.

H. D. Sun, M. L. Hu, X. C. Zhang, and T. D. , Ai-lin 1 treated 32 cases of acute promyelocytic leukemia, p.170, 1992.

I. Tamai and A. Tsuji, Drug delivery through the blood-brain barrier, Advanced Drug Delivery Reviews, vol.19, issue.3, pp.401-424, 1996.
DOI : 10.1016/0169-409X(96)00011-7

H. Tamura, T. Iida, T. Watanabe, and T. Suga, Long-term effects of peroxisome proliferators on the balance between hydrogen peroxide-generating and scavenging capacities in the liver of fischer-344 rats. Toxicology, pp.199-213, 1990.

A. L. Tappel, Selenium???Glutathione Peroxidase: Properties and Synthesis, Curr Top Cell Regul, vol.24, pp.87-97, 1984.
DOI : 10.1016/B978-0-12-152824-9.50015-0

M. Tavassoli, Intravascular Phagocytosis in the Rabbit Bone Marrow: A Possible Fate of Normal Senescent Red Cells, British Journal of Haematology, vol.8, issue.3, pp.323-326, 1977.
DOI : 10.1126/science.179.4076.912

V. J. Thannickal and B. L. Fanburg, Activation of an H 2 O 2 -generating NADH oxidase in human lung fibroblasts by transforming growth factor ?1. The Journal of biological chemistry, pp.30334-30338, 1995.

S. D. Tröster, U. Müller, and J. Kreuter, Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants, International Journal of Pharmaceutics, vol.61, issue.1-2, pp.85-100, 1990.
DOI : 10.1016/0378-5173(90)90047-8

R. L. Virchow and W. Blut, , pp.151-156

Z. G. Wang, R. Rivi, L. Delva, A. Konig, D. A. Scheinberg et al., Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RAR? independent manner, Blood, vol.92, pp.1497-1504, 1998.

Z. G. Wang, D. Ruggero, S. Ronchetti, S. Zhong, M. Gaboli et al., Pml is essential for multiple apoptotic pathways, Nature Genetics, vol.391, issue.3, pp.266-272, 1998.
DOI : 10.1038/35895

S. Waxman and K. C. Anderson, History of the Development of Arsenic Derivatives in Cancer Therapy, The Oncologist, vol.6, issue.90002, pp.3-10, 2001.
DOI : 10.1634/theoncologist.6-suppl_2-3

D. M. Woodcock, M. E. Linsenmeyer, G. Chojnowski, A. B. Kriegler, V. Nink et al., Reversal of multidrug resistance by surfactants, British Journal of Cancer, vol.66, issue.1, pp.62-68, 1992.
DOI : 10.1038/bjc.1992.217

J. D. Wright, F. D. Boudinot, and M. R. Ujhelyi, Measurement and Analysis of Unbound Drug Concentrations, Clinical Pharmacokinetics, vol.30, issue.6, pp.445-462, 1996.
DOI : 10.2165/00003088-199630060-00003

R. Zakharyan, Y. Wu, G. M. Bogdan, and V. Aposhian, Enzymatic Methylation of Arsenic Compounds, Toxicology and Applied Pharmacology, vol.140, issue.1, pp.1029-1038, 1995.
DOI : 10.1006/taap.1996.0199

. Résumé,

, dans le traitement de l'amibiase et en dermatologie (pian) Ce composé commercialisé sous le nom de Balarsen ® était relativement bien toléré en clinique. Récemment, des essais in vitro ont montré que l'arsthinol était plus actif sur les cellules leucémiques (U937 et K562) que le trioxyde d'arsenic inorganique et le mélarsoprol, 1950.

, Cette activité sur les cellules NB4 est à peu près équivalente à celle obtenue avec le trioxyde d'arsenic. Nous avons par ailleurs mis au point des nanosuspensions d'arsthinol qui ont permis de diminuer considérablement les concentrations cérébrales en arsenic après injection I.V. chez la souris. A l'inverse, les concentrations d'arsenic dans la moelle osseuse sont restées importantes. De plus, l'arsthinol sous forme des nanosuspensions reste toujours actif sur les cellules NB4 de LAM 3 . En conséquence, cette distribution tissulaire des nanosuspensions d'arsthinol est plutôt avantageuse pour l'activité antileucémique de l'arsthinol. Enfin, nous avons identifié les métabolites de l, Nous avons constaté que ce composé inhibait la croissance et induisait l'apoptose de ces cellules à des concentrations ? 5µM

. Mots-clés,

. Arsthinol, nanosuspensions, moelle osseuse, barrière hématoencéphalique , métabolites, peroxyde d'hydrogène